Eton Pharmaceuticals Inc (OQ:ETON)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 21925 W Field Pkwy Ste 235
DEER PARK IL 60010-7208
Tel: N/A
IR: See website
Key People
Norbert G. Riedel
Independent Chairman of the Board
Sean E. Brynjelsen
President, Chief Executive Officer, Director
W. Wilson Troutman
Chief Financial Officer, Treasurer, Secretary
Ingrid Hoos
Senior Vice President - Scientific Affairs
Business Overview
Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
Financial Overview
For the six months ended 30 June 2020, Eton Pharmaceuticals Inc revenues decreased 76% to $119K. Net loss increased 29% to $13.8M. Revenues reflect Revenues decrease of 80% to $99K. Higher net loss reflects General and administrative - Balancing v increase of 59% to $5.5M (expense), Interest and other income, net decrease from $244K (income) to $360K (expense).
Employees: 5 as of Jun 30, 2020
Reporting Currency: U.S. Dollars
Enterprise value: $186.64M as of Jun 30, 2020
Annual revenue (TTM): $0.58M as of Jun 30, 2020
EBITDA (TTM): -$20.52M as of Jun 30, 2020
Net annual income (TTM): -$21.44M as of Jun 30, 2020
Free cash flow (TTM): -$17.95M as of Jun 30, 2020
Net Debt Last Fiscal Year: N/A
Shares outstanding: 24,176,033 as of Oct 16, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.